Taraka Gadiraju, MD
Cardiovascular Disease · Tulsa, OKNPI 1356621353
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 288 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,777 and has fallen 90.8% since, to $164 in 2025.
Across 288 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$832
- Novartis$718
- Johnson & Johnson$493
- Amgen$472
- AstraZeneca$378
- Pfizer$367
- plus $3K from 29 others
What the payments were for
- Food & beverage$5,96797%
- Education$1993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 12 | $832 |
| Novartis | 36 | $718 |
| Johnson & Johnson | 29 | $493 |
| Amgen | 28 | $472 |
| AstraZeneca | 12 | $378 |
| Pfizer | 26 | $367 |
| Actelion Pharmaceuticals US, Inc. | 8 | $346 |
| Boston Scientific | 13 | $301 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $256 |
| Abbott | 10 | $219 |
| Boehringer Ingelheim | 12 | $172 |
| Kowa Pharmaceuticals America, Inc. | 13 | $171 |
| Edwards Lifesciences | 2 | $168 |
| Biotronik Inc. | 2 | $155 |
| Amarin Pharma, Inc. | 8 | $151 |
| Merck | 10 | $144 |
| Esperion Therapeutics, Inc. | 7 | $118 |
| Arbor Pharmaceuticals, Inc. | 6 | $90 |
| E.r. Squibb & Sons, L.L.C. | 5 | $73 |
| Chiesi USA, Inc. | 5 | $67 |
| Novo Nordisk | 3 | $52 |
| Regeneron Healthcare Solutions, Inc. | 3 | $44 |
| Lundbeck LLC | 2 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Alnylam Pharmaceuticals Inc. | 2 | $40 |
| Bayer | 2 | $38 |
| Medicure Pharma Inc. | 1 | $37 |
| Philips North America LLC | 2 | $34 |
| Nuwellis, Inc. | 2 | $34 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Kestra Medical Technology Services, Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Cardiac Dimensions, Inc. | 1 | $19 |
| Portola Pharmaceuticals, LLC | 1 | $13 |
| Amryt Pharma Holdings Ltd | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$287
- Resolute$147
- Acticor$139
- Solia$139
- Rivacor$139
- Edora$139
- BioMonitor$139
- UPTRAVI$129
- OPSUMIT$129
- FARXIGA$115
- Edwards SAPIEN 3 Transcatheter Heart Valve$115
- CROSSBOSS$102
How this compares
$6,166 in reported general payments places this provider in the 70th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 402 | $401,303 |
| XareltoRivaroxaban | 133 | $141,825 |
| EntrestoSacubitril/Valsartan | 161 | $132,621 |
| JardianceEmpagliflozin | 109 | $120,150 |
| Repatha SureclickEvolocumab | 51 | $34,076 |
| MultaqDronedarone Hcl | 13 | $17,890 |
| BrilintaTicagrelor | 15 | $12,505 |
| Metoprolol Succinate | 519 | $9,558 |
| Rosuvastatin Calcium | 197 | $8,741 |
| Atorvastatin Calcium | 309 | $7,112 |
| Ezetimibe | 92 | $4,978 |
| LivaloPitavastatin Calcium | 15 | $4,851 |
| Amlodipine Besylate | 504 | $3,992 |
| Carvedilol | 213 | $2,756 |
| Potassium Chloride | 164 | $2,117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $367 | $401,303402 claims |
| Johnson & JohnsonXarelto | $493 | $141,825133 claims |
| NovartisEntresto | $718 | $132,621161 claims |
| Boehringer IngelheimJardiance | $172 | $120,150109 claims |
| Sanofi-aventis U.S. LLCMultaq | $40 | $17,89013 claims |
| AstraZenecaBrilinta | $378 | $12,50515 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $171 | $4,85115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Tulsa
- Frank GaffneyTulsa$211K
- Mohamad KhattabTulsa$47K
- Steve KimTulsa$38K
- Eric AuerbachTulsa$35K
- David WilkettTulsa$25K
- Daniel WildesTulsa$24K
- Thomas KalapuraTulsa$17K
- Heather ChaTulsa$16K
- Christopher HigginsTulsa$13K
- Alan KaneshigeTulsa$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.